Interventional Cardiology Devices – Market Insights – Japan

The Japanese IC device market is driven by an expanding CAD patient pool, the growing prevalence of complex lesions, improving access to treatment, the emerging preference for minimally invasive procedures for treating CAD cases, and the emergence of technologically advanced premium-priced diagnostic and treatment devices providing case-specific diagnosis and intervention for CAD cases with different levels of complexity. However, market revenues will be offset by eroding ASPs due to biennial reimbursement cuts by the MHLW, particularly in the mature PTCA balloon catheter and coronary stent segments, resulting in overall market contraction over the forecast period.

This Medtech 360 Report provides comprehensive data and analysis on the state of the market for IC devices in Japan from 2019 through 2032.

A number of flagship devices were launched in recent years in the highly competitive DES market.

How have the market dynamics changed with new launches?

What competitive strategies competitors are deploying to gain share in this market?

What factors are limiting DES market revenue growth?

New technologies are entering the Japanese IC market.

What recent developments have occurred in the coronary lithotripsy segment of the Japanese IC market following its approval in the country?

How will coronary lithotripsy be adopted after its introduction in Japan?

What factors are influencing the adoption of coronary lithotripsy in Japan?

The increasing adoption of alternative coronary physiology modalities will change the diagnostic market landscape.

How will the adoption of alternative coronary physiology modalities such as resting indices, angiography-based FFR, and noninvasive FFR_CT alter patient and procedure compositions in cardiac catheterization labs?

How will the emergence of noninvasive FFR modalities affect the FFR pressure guidewire market?

New technologies are expected to gain approval in the Japanese IC device market.

Which next-generation BRS are in the developmental pipeline?

How will the utilization of advanced technologies impact the market?

What impact will major clinical trials being conducted have on the market?

What impact will emerging DCBs have on the market?

Biennial MHLW reimbursement cuts will continue to negatively affect the Japanese IC device market.

Which device market has been most affected by the MHLW reimbursement cuts, and to what extent will the different device markets be impacted?

What significant barriers to entry does MHLW reimbursement pose for new competitors in the Japanese IC market?

What strategies are employed by competitors to offset the impact of reimbursement cuts on their revenues?

The Japan IC device market was impacted by the COVID-19 pandemic in the short term.

Has the market been able to recover impacted procedures in 2022?

What is the expected recovery trend for 2023 and beyond?

Table of contents

Interventional Cardiology Devices - Market Insights - Japan

Mayuresh Suresh Parshiwanikar

Mayuresh Parshiwanikar is an associate healthcare research and data analyst on the Cardiovascular Medtech Insights team at Clarivate, specializing in the interventional oncology and interventional cardiology device markets. Mayuresh holds a Master’s degree in Pharmaceutical Biotechnology from National Institute of Pharmaceutical Education and Research, S.A.S. Nagar.

Contact sales Login to access report

Back to all Medtech Insights reports